About Reinnervate
Reinnervate is a company based in Sedgefield (United Kingdom) founded in 2002 was acquired by ReproCELL in August 2014. Reinnervate has raised $2 million across 2 funding rounds from investors including ReproCELL, Parkwalk and NorthStar Education Institute. Reinnervate operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Sedgefield, United Kingdom
- SectorsHealthcare
- Website reinnervate.com
- Social LinkedIn X YouTube
- Acquired by ReproCELL (Aug 2014)
Funding Insights of Reinnervate
Reinnervate has successfully raised a total of $2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2M
- Total Rounds 2
- First Round $2M
(May 2010)
- Investors Count 2
All 2 funding rounds of Reinnervate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2010 | – | Seed | – | – | |
| May 2010 | $2M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Reinnervate
Reinnervate has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ReproCELL, Parkwalk and NorthStar Education Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech companies are invested in by Parkwalk venture capital firm. | – | parkwalkadvisors.com | London, United Kingdom | |
- | – | northstarei.com | - | |
Leading global supplier of iPS-derived cells, stem cell reagents, human biofluids, and 3D cell culture. | 2003 | reprocell.com | Osaka, Japan |
Investor details for Reinnervate
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Reinnervate
4 dated milestones of Reinnervate across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Reinnervate is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Seed,.
- Exit Acquired by ReproCELL.
Competitors of Reinnervate
Reinnervate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Reinnervate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Reinnervate
Websites that share an audience with Reinnervate (reinnervate.com).
Websites whose visitors overlap most with Reinnervate. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ecetoc.org | ecetoc.org | 100% | – | #1,056,532 | – |
| beckmancoulter.com | 100% | 113.9K | #341,469 | View details | |
gentaur.com | gentaur.com | 100% | – | #2,063,864 | – |
wicell.org | wicell.org | 100% | – | #2,266,936 | – |
emdbiosciences.com | emdbiosciences.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Reinnervate
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Reinnervate
10 companies that operate in the same segment as Reinnervate (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Reinnervate
Reinnervate was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Reinnervate is headquartered in Sedgefield, United Kingdom. It is registered at Sedgefield, County Durham, United Kingdom.
Reinnervate is a funded company, having raised a total of $2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on May 2010.
Reinnervate (a ReproCELL company), is a spin-out company from Durham University that offers the Alvetex 3D cell culture platform. The technology is based on the research performed by Prof. Stefan Przyborski who also serves as the companys CSO. Alvetex is a highly porous polystyrene scaffold that is engineered into a 200 micron thick membrane. The scaffold is presented in various ways including multi-welled plates and well inserts, for use with conventional culture plasticware and a novel medium perfusion system. Alvetex 3D cell culture enables scientist to grow tissue-like structures that better mimic in vivo biology than current 2D monolayer methods. The potential to improve the predictive nature of cell-based assays by combining 3D culture and iPSC-derived cell products is attracting a lot of interest in the drug development industry. Reinnervates products are currently used by researchers in over 300 universities and companies globally.
Reinnervate's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes. Reinnervate was acquired by ReproCELL in August 2014.